Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells

ABSTRACT Palbociclib, a selective CDK4/6 kinase inhibitor, is approved in combination with endocrine therapies for the treatment of advanced estrogen receptor positive (ER+) breast cancer. In pre-clinical cancer models, CDK4/6 inhibitors act primarily as cytostatic agents. In two commonly studied ER+ breast cancer cell lines (MCF7 and T47D), CDK4/6 inhibition drives G1-phase arrest and the acquisition of a senescent-like phenotype, both of which are reversible upon palbociclib withdrawal (incomplete senescence). Here we identify an ER+ breast cancer cell line, CAMA1, in which palbociclib treatment induces irreversible cell cycle arrest and senescence (complete senescence). In stark contrast to T47D and MCF7 cells, mTORC1 activity is not stably suppressed in CAMA1 cells during palbociclib treatment. Importantly, inhibition of mTORC1 signaling either by the mTORC1 inhibitor rapamycin or by knockdown of Raptor, a unique component of mTORC1, during palbociclib treatment of CAMA1 cells blocks the induction of complete senescence. These results indicate that sustained mTORC1 activity promotes complete senescence in ER+ breast cancer cells during CDK4/6 inhibitor-induced cell cycle arrest. Consistent with this mechanism, genetic depletion of TSC2, a negative regulator of mTORC1, in MCF7 cells resulted in sustained mTORC1 activity during palbociclib treatment and evoked a complete senescence response. These findings demonstrate that persistent mTORC1 signaling during palbociclib-induced G1 arrest is a potential liability for ER+ breast cancer cells, and suggest a strategy for novel drug combinations with palbociclib.

[1]  A. Teleman,et al.  Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1. , 2020, Cell reports.

[2]  Sarah Alexandrou,et al.  Cyclins E1 and E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets. , 2020, Endocrine-related cancer.

[3]  D. Sabatini,et al.  mTOR at the nexus of nutrition, growth, ageing and disease , 2020, Nature Reviews Molecular Cell Biology.

[4]  D. Fabbro,et al.  PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases , 2019, International journal of molecular sciences.

[5]  P. Romero,et al.  CDK4 regulates lysosomal function and mTORC1 activation to promote cancer cell survival. , 2019, Cancer research.

[6]  Ian H. Guldner,et al.  Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancer , 2019, Nature Communications.

[7]  R. Roskoski.  Targeting ERK1/2 protein-serine/threonine kinases in human cancers. , 2019, Pharmacological research.

[8]  S. Loi,et al.  Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[10]  D. Calvisi,et al.  Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma , 2018, Clinical Cancer Research.

[11]  Adrian V. Lee,et al.  Precision Medicine in Hormone Receptor-Positive Breast Cancer , 2018, Front. Oncol..

[12]  J. Carroll,et al.  Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer , 2018, Molecular Cancer Therapeutics.

[13]  P. Validire,et al.  mTOR pathway activation drives lung cell senescence and emphysema. , 2018, JCI insight.

[14]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[15]  A. Teleman,et al.  CycD/Cdk4 and Discontinuities in Dpp Signaling Activate TORC1 in the Drosophila Wing Disc. , 2017, Developmental cell.

[16]  I. Nakano,et al.  Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms , 2017, Clinical Cancer Research.

[17]  Min Yi,et al.  CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers , 2017, Nature Communications.

[18]  R. Abraham,et al.  Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. , 2017, Cell reports.

[19]  X. Mao,et al.  Novel metabolic and physiological functions of branched chain amino acids: a review , 2017, Journal of Animal Science and Biotechnology.

[20]  E. Knudsen,et al.  The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. , 2017, Trends in cancer.

[21]  A. Yoshida,et al.  Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6. , 2016, Cancer research.

[22]  E. Winer,et al.  Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. , 2016, Cancer cell.

[23]  L. Zender,et al.  mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype , 2015, Nature Cell Biology.

[24]  Massimo Cristofanilli,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[25]  J. Lehár,et al.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.

[26]  R. Puertollano.  mTOR and lysosome regulation , 2014, F1000prime reports.

[27]  J. Campisi.  Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.

[28]  P. Vogt,et al.  Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence , 2012, Cell cycle.

[29]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[30]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[31]  J. Dering,et al.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.

[32]  Marco Pahor,et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice , 2009, Nature.

[33]  M. Blagosklonny,et al.  Rapamycin decelerates cellular senescence , 2009, Cell cycle.

[34]  R. Abraham.  Regulation of the mTOR signaling pathway: from laboratory bench to bedside and back again , 2009, F1000 biology reports.

[35]  M. Blagosklonny,et al.  Growth stimulation leads to cellular senescence when the cell cycle is blocked , 2008, Cell cycle.

[36]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[37]  P. Pandolfi,et al.  Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. , 2007, Cancer research.

[38]  Paul Tempst,et al.  Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.

[39]  B. Clurman,et al.  Cyclin E in normal and neoplastic cell cycles , 2005, Oncogene.

[40]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[41]  D. Guertin,et al.  Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.

[42]  K. Inoki,et al.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. , 2003, Genes & development.

[43]  J. Avruch,et al.  Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.

[44]  D. Sabatini,et al.  mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.

[45]  Hongbing Zhang,et al.  A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. , 2002, Human molecular genetics.

[46]  D. Henley,et al.  Estrogens and cell-cycle regulation in breast cancer , 2001, Trends in Endocrinology & Metabolism.

[47]  G. Benvenuto,et al.  The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination , 2000, Oncogene.